GSK
Latest Trade
41.64USDChange
-0.26(-0.62%)Volume
4,966,889Today's Range
-
42.3852 Week Range
-
48.25As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 41.90 |
|---|---|
Open | 41.89 |
Volume | 4,966,889 |
3M AVG Volume | 60.92 |
Today's High | 42.38 |
Today's Low | 41.61 |
52 Week High | 48.25 |
52 Week Low | 38.43 |
Shares Out (MIL) | 4,989.60 |
Market Cap (MIL) | 106,500.70 |
Forward P/E | -- |
Dividend (Yield %) | 4.86 |
GSK, Clover To Evaluate COVID-19 Vaccine Candidate With Pandemic Adjuvant System
Immatics And GSK Partner To Develop Novel Adoptive Cell Therapies
FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 17.49 |
|---|---|
Price To Sales (TTM) | 2.45 |
Price To Book (MRQ) | 6.76 |
Price To Cash Flow (TTM) | 9.99 |
Total Debt To Equity (MRQ) | 254.57 |
LT Debt To Equity (MRQ) | 196.85 |
Return on Investment (TTM) | 12.32 |
Return on Equity (TTM) | 7.65 |
* GSK FILING ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR TRELEGY ELLIPTA USE IN ADULT PATIENTS WITH ASTHMA
* GSK SAYS GLOBAL COLLABORATION LAUNCHED TO DEVELOP TREATMENT REGIMENS FOR TUBERCULOSIS
* EUROPEAN MEDICINES AGENCY ACCEPTS SUBMISSION OF GSK'S MARKETING AUTHORISATION APPLICATION FOR ZEJULA (NIRAPARIB) IN FIRST-LINE MAINTENANCE TREATMENT FOR WOMEN WITH PLATINUM-RESPONSIVE ADVANCED OVARIAN CANCER
Private equity-backed generic drugmaker Stada <STAGn.D> said it has agreed to buy 15 consumer healthcare products from British drugmaker GlaxoSmithKline <GSK.L> to further strengthen its prescription-free drugs business in Europe.
China's Clover Biopharmaceuticals said https://www.businesswire.com/news/home/20200224005319/en on Monday it will work with Britain's GlaxoSmithKline on a research tie-up that will develop the Chinese company's protein-based coronavirus vaccine candidate "COVID-19 S-Trimer".
China's Clover Biopharmaceuticals said https://www.businesswire.com/news/home/20200224005319/en on Monday it had entered into a research tie-up with Britain's GlaxoSmithKline for its protein-based coronavirus vaccine candidate "COVID-19 S-Trimer".
GlaxoSmithKline <GSK.L> missed fourth-quarter earnings forecasts on Wednesday as cheap competition to the British drugmaker's respiratory medicines offset strong growth in sales of its shingles vaccine.
GlaxoSmithKline Plc's quarterly profit fell short of analysts' expectations on Wednesday, and the drugmaker said it has begun its planned split into two companies following the merger of its over-the-counter products into a venture with Pfizer.
The European Union's top court set criteria on Thursday to resolve a dispute in Britain over deals GlaxoSmithKline <GSK.L> struck with rival drugmakers to delay the launch of generic drugs.
British drugmaker GlaxoSmithKline may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.
Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
In December 2017, U.S. District Judge Cynthia Rufe of Philadelphia seemingly drove a stake through the heart of litigation by two employee healthcare funds suing GlaxoSmithKline over its marketing of the diabetes drug Avandia. The plans, which sued back in 2010, alleged...
GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.
GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex.
GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.
German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.
GlaxoSmithKline PLC on Tuesday said it had reached an eve-of-trial settlement resolving claims by several insurers that it misled them into paying $2.7 billion for drugs made at a Puerto Rico plant in an "egregious" violation of federal manufacturing standards.
GlaxoSmithKline Plc is set to face trial on Tuesday in a multibillion-dollar lawsuit alleging it misled insurers into paying for drugs made in "egregious" violation of federal quality standards, with a lawyer better known for securing big verdicts against drugmakers leading...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.